DMSO, a natural compound derived from trees, has been identified in over 11,000 scientific studies since the 1960s as possessing remarkable therapeutic potential for tissue regeneration, cancer remission, and chronic pain relief. Despite this extensive research, pharmaceutical companies have systematically blocked its widespread medical use through regulatory maneuvers and misleading safety claims.

The U.S. Food and Drug Administration (FDA) has approved DMSO for bladder inflammation but restricts its application in human medicine due to perceived safety concerns that have been widely debunked. This suppression persists despite evidence showing DMSO’s ability to dissolve and transport compounds deep into tissues—a property demonstrated in studies where it induced complete remission of cervical cancer by triggering apoptosis (cancer cell suicide).

Veterinarians and sports medicine professionals have long utilized DMSO for treating injuries and chronic pain without adverse effects. However, the pharmaceutical industry has maintained that DMSO threatens its profit margins due to its effectiveness as an anti-inflammatory and regenerative agent, properties that could undermine costly chemotherapy treatments.

DMSO’s non-toxic nature and capacity to reactivate the body’s natural healing processes have made it a target for regulatory suppression. Industry insiders report that DMSO outperforms conventional medications at a fraction of their cost, yet its potential remains hidden from mainstream medical practice.

This article was originally written by Mike Adams.